We found that the modified HSCs carrying the ablated CCR5 persisted for at least 19 months after transplantation, supporting the long-term engraftment and safety of clustered regularly interspaced short palindromic repeat (CRISPR)-edited HSCs, which gives us confidence that this strategy is promising for treating HIV infection in the future. This evidence concerns the gene CCR5 and HIV infectious disease.